Login to Your Account

Liberty from itching? Sanofi, Regeneron start pivotal dupilumab trials

By Michael Fitzhugh
Staff Writer

Monday, October 20, 2014
Regeneron Pharmaceuticals Inc. and Sanofi SA began dosing patients in the first of several planned phase III studies of the potential blockbuster dupilumab (REGN668/SAR231893).

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription